Skip To Main Content
Thibeault Ferhat-Berland on Muck Rack

Thibeault Ferhat-Berland

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Thibeault

Contact Thibeault, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the

|
By Jesús Duque-Afonso, Jürgen Finke, Jacques-Emmanuel Galimard, Francesca Kinsella, Deborah Richardson, Friedrich Stölzel, Eleni Tholouli, Caroline Besley, Matthias Eder, Emma Nicholson, Robert Zeiser, Adrian Bloor, Charles Crawley, Katherine Clesham, Jennifer Byrne, Elisa M. Sala, Caroline Pabst, Jan Vydra, Eva Wagner-Drouet, Alain P Gadisseur, Alexandros Spyridonidis, Eolia Brissot, Arnon Nagler, Mohamad Mohty Verified, Fabio Ciceri, Thibeault Ferhat-Berland, Patrick Medd
| Nature Verified
Abstract Allogeneic hematopoietic cell transplantation is a potentially curative therapy for acute myeloid leukemia (AML), but its success is limited by graft-versus-host disease (GvHD). Optimal in vivo T-cell depletion strategies for GvHD prophylaxis given with conditioning regimens remain under investigation.
Open in Who Shared Issue with article?
See all 1 articles